kronosbio.comHealthcareFounded: 2017Funding to Date: $123MM
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.
For more details on financing and valuation for Kronos Bio, register or login.
View Enterprise Value for Kronos Bio.
To read this article and more news on Kronos Bio, register or login.